🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)

RecruitingNAAges 20 Years - 80 YearsAllYonsei University
NCT03385018 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Although Laparoscopic gastrectomy for both early and locally advanced gastric cancer has gained popularity, the use of laparoscopic total gastrectomy for proximal advanced gastric cancer is still limited to some experienced surgeons, because of its technical difficulties in D2 lymph node dissection and anastomoses. Some retrospective and cohort studies regarding laparoscopic total gastrectomy with lymph node dissection suggested the likelihood of application of laparoscopic surgery for proximal gastric cancer. However, there has been no randomized clinical trial comparing results of laparoscopic total gastrectomy with D2 lymph node dissection with open conventional surgery. Therefore, we aimed to verify the efficacy of laparoscopic total gastrectomy with D2(D2-10) lymph node dissection, technical and oncologic safety compared with open surgery via multicenter randomized clinical trial.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients who are over 20 and below 80 years old * Patients who have performance status of ECOG 0 or 1 * Patients with American Society of Anesthesiology score of class I to III * Patients who are diagnosed with gastric adenocarcinoma not involving Z-line by endoscopy with biopsy * Patients with tumors which can be curatively resected by total gastrectomy with lymph node dissection based on preoperative study * Patients who have primary gastric carcinoma invaded into over muscle propria, and not into adjacent organ in preoperative studies (cT2 \~ cT4a) * Patients who have no metastasis to lymph nodes or limited metastasis to perigastric lymph node metastasis in preoperative studies (cN0 \~ cN2) * Patients who agree with participating in the clinical study with informed consents * Patients who can be followed for at least 3 years after study enrollment Exclusion Criteria: * Patients who have possibility of distant metastasis in preoperative studies * Patients who have history of gastric resection with any cause * Patients who have complications (bleeding or obstruction) of gastric cancer * Patients who are treated by chemo(radio)therapy or endoscopic submucosal dissection for gastric cancer * Patients who are diagnosed and treated with other malignancies within 5 years * Vulnerable patients * Patients who participating or participated in other clinical trial within 6 months
💊

What it tests

  • Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach
  • Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
📍

Where

1 site
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy